Paul l. Berns

Paul l. Berns is a declared insider at 6 companies (board member); the most frequent names are Anacor Pharmaceuticals, Inc., Neumora Therapeutics, Inc. and Kardigan, Inc. In total, 16 filings cover trades dated from 4 January 2016 to 22 June 2026.

Market trades split into 1 purchase and 6 sales (€240k). The totals do not cover 4 filings with an undisclosed amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 4 share grants. So far in 2026, the count stands at 1 purchase and 1 sale.

On 24 June 2026 came the latest disclosure, an open-market purchase in Kardigan, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.